These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15027061)

  • 1. Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.
    Marks JD
    Mov Disord; 2004 Mar; 19 Suppl 8():S101-8. PubMed ID: 15027061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and partial characterization of high-affinity monoclonal antibodies for botulinum toxin type A and their use in analysis of milk by sandwich ELISA.
    Stanker LH; Merrill P; Scotcher MC; Cheng LW
    J Immunol Methods; 2008 Jul; 336(1):1-8. PubMed ID: 18452945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin type A.
    Wu HC; Yeh CT; Huang YL; Tarn LJ; Lung CC
    Appl Environ Microbiol; 2001 Jul; 67(7):3201-7. PubMed ID: 11425742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.
    Mullaney BP; Pallavicini MG; Marks JD
    Infect Immun; 2001 Oct; 69(10):6511-4. PubMed ID: 11553596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.
    Levy R; Forsyth CM; LaPorte SL; Geren IN; Smith LA; Marks JD
    J Mol Biol; 2007 Jan; 365(1):196-210. PubMed ID: 17059824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and characterization of monoclonal antibodies against botulinum neurotoxin type A (BoNT/A).
    Wang JL; Kang L; Jia HL
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Jan; 20(1):83-5. PubMed ID: 15182629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.
    Nowakowski A; Wang C; Powers DB; Amersdorfer P; Smith TJ; Montgomery VA; Sheridan R; Blake R; Smith LA; Marks JD
    Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11346-50. PubMed ID: 12177434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin.
    Garcia-Rodriguez C; Levy R; Arndt JW; Forsyth CM; Razai A; Lou J; Geren I; Stevens RC; Marks JD
    Nat Biotechnol; 2007 Jan; 25(1):107-16. PubMed ID: 17173035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.
    Dolimbek BZ; Aoki KR; Steward LE; Jankovic J; Atassi MZ
    Mol Immunol; 2007 Feb; 44(5):1029-41. PubMed ID: 16647121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary non-response due to development of neutralising antibodies to botulinum toxin A during treatment of children with cerebral palsy.
    Herrmann J; Mall V; Bigalke H; Geth K; Korinthenberg R; Heinen F
    Neuropediatrics; 2000 Dec; 31(6):333-4. PubMed ID: 11508557
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor.
    Sharma R; Zhao H; Al-Saleem FH; Ubaid AS; Puligedda RD; Segan AT; Lindorfer MA; Bermudez R; Elias M; Adekar SP; Simpson LL; Taylor RP; Dessain SK
    Mol Immunol; 2014 Feb; 57(2):247-54. PubMed ID: 24184879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation and characterization of a novel human monoclonal antibody that neutralizes tetanus toxin.
    Simpson LL; Lake P; Kozaki S
    J Pharmacol Exp Ther; 1990 Jul; 254(1):98-103. PubMed ID: 1694896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitope mapping of human follicle stimulating hormone-alpha using monoclonal antibody 3A identifies a potential receptor binding sequence.
    Weiner RS; Dias JA; Andersen TT
    Endocrinology; 1991 Mar; 128(3):1485-95. PubMed ID: 1705506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies against botulinum neurotoxin type A as a cause of treatment failure after the first detrusor injection.
    Schulte-Baukloh H; Bigalke H; Heine G; Pape D; Stuerzebecher B; Miller K; Knispel HH
    Urology; 2007 Mar; 69(3):575.e13-5. PubMed ID: 17382174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sensitive sandwich enzyme immunoassay for free or complexed Clostridium botulinum neurotoxin type A.
    Volland H; Lamourette P; Nevers MC; Mazuet C; Ezan E; Neuburger LM; Popoff M; Créminon C
    J Immunol Methods; 2008 Jan; 330(1-2):120-9. PubMed ID: 18093612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains.
    Dolimbek GS; Dolimbek BZ; Aoki KR; Atassi MZ
    Immunol Invest; 2005; 34(2):119-42. PubMed ID: 15921155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a highly neutralizing single monoclonal antibody to botulinum neurotoxin type A.
    Brier S; Rasetti-Escargueil C; Wijkhuisen A; Simon S; Marechal M; Lemichez E; Popoff MR
    FASEB J; 2021 May; 35(5):e21540. PubMed ID: 33817838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus.
    Gromowski GD; Barrett AD
    Virology; 2007 Sep; 366(2):349-60. PubMed ID: 17719070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?
    Lange O; Bigalke H; Dengler R; Wegner F; deGroot M; Wohlfarth K
    Clin Neuropharmacol; 2009; 32(4):213-8. PubMed ID: 19620852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of monoclonal antibodies as probes for the structure and biological activity of botulinum neurotoxin.
    Simpson LL; Kamata Y; Kozaki S
    J Pharmacol Exp Ther; 1990 Oct; 255(1):227-32. PubMed ID: 2213557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.